Connect Biopharma Holdings Limited
CNTB
$2.12
-$0.08-3.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 169.00K | 0.00 | 16.00K | 48.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 169.00K | 0.00 | 16.00K | 48.00K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 169.00K | 0.00 | 16.00K | 48.00K | -- |
| SG&A Expenses | 4.75M | 4.24M | 6.58M | 4.70M | 4.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.78M | 15.53M | 17.69M | 13.47M | 11.45M |
| Operating Income | -19.61M | -15.53M | -17.68M | -13.42M | -11.45M |
| Income Before Tax | -19.35M | -15.08M | -17.14M | -12.84M | -10.22M |
| Income Tax Expenses | 48.00K | 27.00K | 61.00K | 55.00K | 54.00K |
| Earnings from Continuing Operations | -19.40M | -15.11M | -17.20M | -12.90M | -10.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.40M | -15.11M | -17.20M | -12.90M | -10.27M |
| EBIT | -19.61M | -15.53M | -17.68M | -13.42M | -11.45M |
| EBITDA | -19.44M | -15.35M | -17.50M | -13.25M | -11.27M |
| EPS Basic | -0.34 | -0.27 | -0.31 | -0.23 | -0.19 |
| Normalized Basic EPS | -0.21 | -0.17 | -0.19 | -0.14 | -0.12 |
| EPS Diluted | -0.34 | -0.27 | -0.31 | -0.23 | -0.19 |
| Normalized Diluted EPS | -0.21 | -0.17 | -0.19 | -0.14 | -0.12 |
| Average Basic Shares Outstanding | 56.55M | 56.07M | 55.72M | 55.50M | 55.35M |
| Average Diluted Shares Outstanding | 56.55M | 56.07M | 55.72M | 55.50M | 55.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |